LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Max Reinhardt as President of the Global Spine business effective June 10, 2024. Reinhardt will serve on the Executive Leadership Team and be responsible for leading SeaSpine, the Company’s global spine and biologics business..

德克萨斯州路易斯维尔——（商业新闻短讯）——全球领先的脊柱和骨科公司Orthofix Medical Inc.（纳斯达克：OFIX）今天宣布任命马克斯·莱因哈特（Max Reinhardt）为全球脊柱业务总裁，自2024年6月10日起生效。莱因哈特（Reinhardt）将担任高管领导团队成员，负责领导SeaSpine公司的全球脊柱和生物制品业务。。

Reinhardt’s experience spans more than 30 years in MedTech and pharmaceuticals, assuming positions of increasing responsibility at Johnson & Johnson, including serving as Worldwide President, DePuy Synthes Spine, achieving the number two market share position in the competitive spine market. Additionally, Reinhardt served as Vice President, Marketing U.S.

莱因哈特（Reinhardt）在医学技术和制药领域拥有30多年的经验，在强生公司担任越来越重要的职位，包括担任全球总裁DePuy Synthes Spine，在竞争激烈的Spine市场上占据第二大市场份额。此外，莱因哈特还担任美国市场营销副总裁。

Orthopedics, and Global Franchise Leader and Worldwide President of Joint Reconstruction, Sports Medicine and Power Tools. Reinhardt has worked closely with key opinion leaders and launched market-leading biologics and implant solutions in spine surgery, joint replacement, orthopedic trauma and early intervention, supported by a robust technique-based professional education agenda..

骨科，全球特许经营领导者，关节重建，运动医学和电动工具的全球总裁。莱因哈特与关键意见领袖密切合作，推出了脊柱外科、关节置换、骨科创伤和早期干预领域的市场领先生物制剂和植入物解决方案，并得到了强大的基于技术的专业教育议程的支持。。

“Max brings strong leadership and a proven track record of success to our global spine business,” said Orthofix President and CEO Massimo Calafiore. “He brings a wealth of experience in driving innovation while continually executing focused strategies to drive commercial success. I look forward to the guidance and expertise he will bring to our organization as we continue to accelerate and position Orthofix as one of the leading spine companies in the market.”.

Orthofix总裁兼首席执行官马西莫·卡拉菲奥（MassimoCalafiore）表示：“马克斯（Max）为我们的全球脊柱业务带来了强大的领导力和成功的业绩记录。”。“他在推动创新方面积累了丰富的经验，同时不断执行有针对性的战略以推动商业成功。随着我们继续加速发展，并将Orthofix定位为市场上领先的脊柱公司之一，我期待着他为我们的组织带来指导和专业知识。”。

Prior to his experience with Johnson & Johnson, Reinhardt had senior leadership positions with Steris and Olympus in Europe. Most recently, Reinhardt served in different leadership roles for Pacira Biosciences, a company focused on providing innovative non-opioid pain management solutions.

在加入强生公司之前，莱因哈特曾在欧洲的斯特里斯和奥林巴斯担任高级领导职务。最近，莱因哈特在Pacira Biosciences担任不同的领导角色，Pacira Biosciences是一家专注于提供创新的非阿片类药物疼痛管理解决方案的公司。

“I am delighted to have the opportunity to lead the talented spine team at Orthofix as we continue to innovate and introduce differentiated products and procedurally integrated solutions to the market to solve complex spine problems,” said Reinhardt. “I believe the company has a strong foundation and is well positioned for growth in the years ahead.

莱因哈特说：“我很高兴有机会领导Orthofix的优秀脊柱团队，我们将继续创新，向市场推出差异化产品和程序集成解决方案，以解决复杂的脊柱问题。”。“我相信该公司有着坚实的基础，在未来几年的发展中处于有利地位。

I look forward to working with our dedicated team members to deliver new product solutions and provide exceptional support for our surgeon customers and their patients.”.

我期待着与我们专注的团队成员合作，提供新的产品解决方案，并为我们的外科医生客户及其患者提供卓越的支持。”。

Reinhardt earned his undergraduate diploma from Sparsholt College, Hampshire, U.K. and a Master of Science degree from the University of Hull, U.K.

莱因哈特（Reinhardt）获得了英国汉普郡斯巴索尔特学院（Sparsholt College）的本科文凭，以及英国赫尔大学（University of Hull）的理学硕士学位。

About Orthofix

关于Orthofix

Orthofix is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Its products are distributed in more than 60 countries worldwide.

Orthofix是一家全球领先的脊柱和骨科公司，拥有生物制剂、创新脊柱硬件、骨生长疗法、专业骨科解决方案和领先的外科导航系统的综合投资组合。其产品分布在全球60多个国家。

The Company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics.

该公司总部位于德克萨斯州路易斯维尔（Lewisville），从事一般业务、产品开发、医学教育和制造，主要办事处位于加利福尼亚州卡尔斯巴德（Carlsbad），专注于脊柱和生物制品产品创新和外科医生教育，以及意大利维罗纳（Verona），重点是骨科产品创新、生产和医学教育。

The combined Company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Maidenhead, UK, Munich, Germany, Paris, France and São Paulo, Brazil..

合并后公司的全球研发、商业和制造足迹还包括位于加利福尼亚州欧文、加拿大多伦多、加利福尼亚州桑尼维尔、英国梅登黑德、德国慕尼黑、法国巴黎和巴西圣保罗的设施和办事处。。

Forward-Looking Statements

前瞻性声明

This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “continue” or other comparable terminology.

本新闻稿可能包括经修订的《1934年证券交易法》第21E节和经修订的《1933年证券法》第27A节所指的前瞻性声明。在某些情况下，您可以通过术语来识别前瞻性陈述，例如“可能”、“将”、“应该”、“预期”、“计划”、“预期”、“相信”、“估计”、“项目”、“打算”、“预测”、“潜力”、“继续”或其他类似术语。

Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.

Orthofix提醒您，本新闻稿中包含的声明不是对历史事实的描述，而是基于公司当前预期和假设的前瞻性声明。本新闻稿中包含的每一项前瞻性声明都存在风险和不确定性，这些风险和不确定性可能导致实际结果与该声明中明示或暗示的结果产生重大差异。

Applicable risks and uncertainties include, among others: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; and the risks identified under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on March 5, 2024.

适用的风险和不确定性包括：新推出的产品能够按照设计和预期执行，并满足外科医生和患者的需求，包括由于缺乏强有力的临床验证；以及Orthofix Medical Inc.截至2023年12月31日财年的10-K表年度报告中“风险因素”标题下确定的风险，该报告于2024年3月5日提交给美国证券交易委员会（SEC）。

The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law..

公司向证券交易委员会提交的公开文件可在www.sec.gov上查阅。请注意不要过度依赖前瞻性声明，这些声明仅在作出之日起生效。Orthofix不打算修改或更新本新闻稿中规定的任何前瞻性声明，以反映本新闻稿日期后发生的事件或情况，法律可能要求的除外。。